
Modified-release dosage forms present new opportunities for drug developers and can help overcome challenges, such as short biological half-life or poor bioavailability due to degradation in the stomach.
Torkel Gren is senior director, Technology Officer & Strategic Investments at Recipharm.

Published: June 30th 2021 | Updated: